Abrocitinib: Manufacturing and Patent Landscape
Abrocitinib, a Janus kinase 1 (JAK1) inhibitor used to treat atopic dermatitis, is protected by several patents covering its synthesis and pharmaceutical composition. The large-scale manufacturing process for abrocitinib involves specific chemical steps and formulations designed for efficient and consistent production.
How is Abrocitinib Synthesized?
The synthesis of abrocitinib typically involves a multi-step chemical process. One described method begins with (2-chloro-5-(trifluoromethyl)pyridin-3-yl)methanol, which undergoes reactions to form intermediate compounds. These intermediates are then further processed, including amidation and coupling reactions, to yield the final abrocitinib molecule. The process requires careful control of reaction conditions, reagents, and purification techniques to ensure the purity and yield of the active pharmaceutical ingredient [1].
What Patents Protect Abrocitinib?
Abrocitinib is covered by multiple patent families. These patents address different aspects of the drug, including its chemical structure, methods of use, and manufacturing processes. For example, patents have been granted for specific polymorphic forms of abrocitinib and for novel synthetic routes. These patents are crucial for securing market exclusivity for the drug manufacturer. Information on specific patent numbers and their expiration dates can be found through patent databases, such as those accessible via DrugPatentWatch.com [2].
When Might Abrocitinib Face Generic Competition?
The timeline for generic competition for abrocitinib depends on the expiration of its key patents and any potential patent challenges or extensions. Drug patents generally have a lifespan of 20 years from the filing date, but various mechanisms like Patent Term Extensions (PTE) can prolong this period. Generic manufacturers often begin developing their versions of a drug in anticipation of patent expiry. The specific patent landscape for abrocitinib, detailing the expiration dates of relevant patents, can be researched through resources like DrugPatentWatch.com [2].
What Are the Key Components of Abrocitinib's Pharmaceutical Composition?
The pharmaceutical composition of abrocitinib refers to the final dosage form of the drug, typically tablets. These compositions include the active ingredient, abrocitinib, along with various excipients. Excipients are inactive ingredients that serve essential functions such as binding the tablet together, aiding in dissolution, providing stability, and facilitating the manufacturing process. Patents related to pharmaceutical composition may cover specific formulations that enhance the drug's delivery, stability, or patient compliance [1].